Method of preventing acute rejection following solid organ transplantation
US6013256A · kind A · utility
22Cited by
6References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 1997 |
| Grant date | Jan 11, 2000 |
| Priority date | — |
| Expiry date | Sep 22, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of preventing acute rejection following renal or other solid organ transplantation. The methods entail administering, e.g., intravenously, to a transplant patient a monoclonal antibody which binds to the p55 subunit of the human interleukin-2 (IL-2) receptor of human T lymphocytes. The monoclonal antibody is preferably a chimeric or humanized antibody that blocks binding of IL-2 to the IL-2 receptor. In some methods, a single dose of about 1 mg/kg of antibody is administered about every other week, commencing immediately prior to transplantation and continuing until 8 weeks after transplantation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.